Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - A sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial

Breast Cancer Research and Treatment

Volumn 85, Issue 3, 2004, Pages 247-254

  Thürlimann, Beat ^a   Hess, Dagmar ^a   Köberle, Dieter ^a   Senn, Isabella ^a   Ballabeni, Pierluigi ^b   Pagani, Olivia ^c   Perey, Lucien ^d   Aebi, Stefan ^e   Rochlitz, Christoph ^f   Goldhirsch, Aron ^c,g  

^a Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c Ospedale Beata Vergine   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f Division of Oncology   (Switzerland)

^g REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

Advanced; Anastrozole; Arimidex; Breast cancer; Endocrine therapy; Hormone responsive; Postmenopausal; SAKK; Sequencing; Tamoxifen

Indexed keywords

ANASTROZOLE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

ARTICLE; BREAST CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HORMONAL THERAPY; HUMAN; METASTASIS; PHARMACEUTICAL CARE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RETROSPECTIVE STUDY; RISK; SURVIVAL; ADULT; AGED; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASM; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SWITZERLAND;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CROSS-OVER STUDIES; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; SURVIVAL RATE; SWITZERLAND; TAMOXIFEN; TRIAZOLES;

EID: 3342946114     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000025420.78346.f9     Document Type: Article

References (9)

1. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83: 1142-1152, 1998
2. Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women - results of the TARGET (Tamoxifen or Arimidex™ Randomised Group Efficacy and Tolerability) study. J Clin Oncol 18: 3748-3757, 2000
3. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicentre randomized trial. J Clin Oncol 18: 3758-3776, 2000
4. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M, Arimidex Writing Committee, Investigators Committee Members: Anastrozole (Arimidex) is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast cancer: Results of two randomized trials designed for combined analysis. Cancer 92: 2247-2258, 2001
5. Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thurlimann B: Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 39: 1684-1689, 2003
6. Thürlimann B, Robertson JFR, Nabholtz JM, Buzdar A, Bonneterre J, on behalf of the Arimidex Study Group: Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 39: 2310-2317, 2003
7. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453-461, 1998
8. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 18: 1399-1411, 2000
9. Thürlimann B, Beretta K, Bacchi M, Castiglione-Gertsch M, Goldhirsch A, Jungi WF, Cavalli F, Senn HJ, Fey M, Lohnert T: First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 7: 471-179, 1996